FEQ1.F LABORATORIO REIG J.EO 05
- Market cap
- EUR 209M
- P/E
- 31.9x
- P/B
- 0.94x
- ROE
- 2.8%
- Dividend yield
- 0.02%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is FEQ1.F undervalued?
Graham numberFEQ1.F trades 15.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LABORATORIO REIG J.EO 05 fundamental analysis
No fundamental analysis for LABORATORIO REIG J.EO 05 yet.
LABORATORIO REIG J.EO 05 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LABORATORIO REIG J.EO 05
Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products, raw materials, biotechnological products, nutritional supplements, health products, medical devices, cosmetics, parapharmaceuticals, food, and other products. Its products also include pharmaceutical technologies products, such as antibiotics, and injectables and other products; specialty pharmacare products, which include skin, hair, nails, joint …
Full company profileLABORATORIO REIG J.EO 05 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
LABORATORIO REIG J.EO 05 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 236M | 271M | 316M | 339M | 331M | 337M |
| Gross Profit | 145M | 157M | 179M | 196M | 196M | 218M |
| Operating Income | 9.37M | 9.21M | 12.4M | 15.1M | 6.80M | 11.0M |
| EBITDA | - | 30.5M | 34.4M | 36.2M | 32.5M | 34.3M |
| Net Income | 5.09M | 8.11M | 9.41M | 10.4M | 5.02M | 6.19M |
| EPS | 0.07 | 0.10 | 0.12 | 0.13 | 0.06 | 0.08 |
| Balance Sheet | ||||||
| Total Assets | 325M | 321M | 331M | 345M | 395M | 421M |
| Total Liabilities | 136M | 127M | 126M | 131M | 174M | 197M |
| Shareholders' Equity | 189M | 195M | 204M | 214M | 218M | 221M |
| Cash & Short-term Investments | 5.07M | 6.45M | 5.53M | 10.5M | 10.5M | 13.6M |
| Cash Flow | ||||||
| Operating Cash Flow | 14.5M | 16.1M | 19.1M | 31.3M | 1.51M | - |
| Capital Expenditure | 19.8M | 11.4M | 12.8M | 20.8M | 18.3M | 0.00 |
| Free Cash Flow | -5.27M | 4.75M | 6.35M | 10.6M | -16.8M | - |
| Ratios | ||||||
| ROE | 2.7% | 4.2% | 4.6% | 4.9% | 2.3% | 2.8% |
| ROA | 1.6% | 2.5% | 2.8% | 3.0% | 1.3% | 1.5% |
| Net Profit Margin | 2.2% | 3.0% | 3.0% | 3.1% | 1.5% | 1.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
LABORATORIO REIG J.EO 05 dividends
- Dividend yield
- 0.02%
- Forward dividend
- 0.02 EUR
- Payout ratio
- 0.6%
- Ex-dividend date
- May 21, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 32.0K | 0.00 | 0.6% |
| 2024 | EUR 25.0K | 0.00 | 0.2% |
| 2023 | EUR 41.0K | 0.00 | 0.4% |
| 2022 | EUR 53.0K | 0.00 | 0.7% |
| 2021 | EUR 55.0K | 0.00 | 1.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns LABORATORIO REIG J.EO 05
- Insiders 78.46%
- Institutions 5.85%
- Public & others 15.69%
- Shares outstanding 82.1M
- Free float 22.0M
LABORATORIO REIG J.EO 05 company profile
- Company name
- LABORATORIO REIG J.EO 05
- Ticker
- FEQ1.F
- ISIN
- ES0165359029
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,512
- Fiscal year end
- December
- Address
- Gran Capita, Street 10, Barcelona, Spain
- Phone
- 34 93 480 67 10
- Website
- reigjofre.com/en
About LABORATORIO REIG J.EO 05
Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products, raw materials, biotechnological products, nutritional supplements, health products, medical devices, cosmetics, parapharmaceuticals, food, and other products. Its products also include pharmaceutical technologies products, such as antibiotics, and injectables and other products; specialty pharmacare products, which include skin, hair, nails, joint health and pain, and women's health; and food supplements under the Forté Pharma brand. In addition, the company provides CDMO and CMO services; and management and administration services. It sells its products through business partners. The company was founded in 1929 and is headquartered in Barcelona, Spain. Laboratorio Reig Jofre, S.A. operates as a subsidiary of Reig Jofre Investments SL.
LABORATORIO REIG J.EO 05 management
3- Mr. Ignasi Biosca ReigCEO & Executive Director
- Ms. Inma Santa-PauDirector of Communication & Investor Relations
- Mr. Inaki Frias InchaustiNon-Director Secretary